Expert Analysis

Acute Leukemias/Myelodysplastic Syndromes

Source: CCO Independent Conference Coverage of the American Society of Hematology 2008 Annual Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Acute Leukemias/Myelodysplastic Syndromes

Program Director: Roy A. Beveridge, MD

Faculty:

Hagop M. Kantarjian, MD
Alan F. List, MD
Martin S. Tallman, MD

Robert S. Mocharnuk, MD

CREDIT INFORMATION

Release Date: 02/05/09

Expiration Date: 02/04/10

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.25 Nursing contact hours

Pharmacists: 1.25 contact hours (0.13 CEUs)

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize studies on the treatment of newly diagnosed acute promyelocytic leukemia
List the agents that have been added to standard anthracycline/cytarabine therapy in first-line treatment of acute myeloid leukemia
Describe the findings of studies of hypomethylating agents in acute myeloid leukemia and in myelodysplastic syndromes
Discuss therapeutic advances for thrombocytopenia and iron overload in myelodysplastic syndrome patients
Identify novel approaches for the treatment of myelofibrosis

Topics covered include:

Arsenic Trioxide for Treatment of Patients With Acute Promyelocytic Leukemia in Either the First-line or Relapsed Settings
Addition of Single Agents to Standard Anthracycline Plus Cytarabine in Newly Diagnosed Acute Myeloid Leukemia
Clofarabine Monotherapy in Previously Untreated Older AML Patients
Azacitidine or Decitabine Treatment for AML Patients
Decitabine vs Best Supportive Care in Elderly Patients With MDS
Effects of Continued Azacitidine Cycles in Higher-Risk MDS Patients
Azacitidine Maintenance for High-Risk MDS or AML in CR After Induction Chemotherapy
Romiplostim for Patients With Low- or Intermediate-Risk MDS
Long-term Cytogenetic Follow-up of MDS Patients With 5q Deletion
Effect of Iron Overload and Transfusion Dependency on Survival and Leukemic Evolution
Novel Therapies in Myelofibrosis
Concluding Remarks

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.